Stifel raised the firm’s price target on Cytokinetics (CYTK) to $98 from $95 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics: Strong Myqorzo Launch, Expanding Market Access, and Upcoming HCM Milestones Underpin Buy Rating
- Cytokinetics price target raised to $96 from $88 at Citizens
- Cytokinetics (CYTK) Q4 Earnings Cheat Sheet
- Cytokinetics price target raised to $101 from $95 at RBC Capital
- Cytokinetics transferred with Overweight at Barclays